KR102152947B1 - Compositions for Preventing, Improving or Treating Non-Alcoholic Fatty Liver Disease Comprising Combined Extracts of Peach Blossom and Lotus Leaf - Google Patents

Abstract

The present invention relates to a composition for the prevention, improvement or treatment of obesity or metabolic disease, comprising the dohwa and lower leaf complex extract or a fraction thereof as an active ingredient. Dohwa and lower lobe complex extract of the present invention or its fractions have excellent efficacy against obesity or metabolic diseases, are derived from natural products, and have no side effects, and thus prevent or improve a pharmaceutical composition for the prevention or treatment of metabolic diseases or obesity or metabolic diseases It can be used in various ways as a food composition for use.

Description

Compositions for Preventing, Improving or Treating Non-Alcoholic Fatty Liver Disease Comprising Combined Extracts of Peach Blossom and Lotus Leaf}

The present invention relates to a pharmaceutical composition for the prevention or treatment of obesity or metabolic diseases, or a food composition for preventing or improving obesity or metabolic diseases, comprising a complex extract of Peach Blossom and Lotus leaf or a fraction thereof as an active ingredient. About.

In modern society, as a result of the change to a meat-oriented diet, the intake of calories has become excessive, while the amount of exercise has become insufficient, and the onset of metabolic diseases including various diseases such as obesity, diabetes, hyperlipidemia, non-alcoholic fatty liver, and dyslipidemia is rapidly increasing.

Obesity refers to a state in which excess energy is accumulated as fat in the body due to the large amount of energy intake compared to the amount of energy consumed. The pharmacological mechanisms of obesity drugs currently used are largely 1) inhibition of fat absorption, 2) promotion of fat breakdown and heat generation, 3) regulation of appetite and satiety, 4) inhibition of protein metabolism, and 5) 　regulation of emotions related to food intake. I can share. Representative obesity treatments include Xenical™, which inhibits fat absorption, and Reductil™, which suppresses appetite by stimulating the sympathetic nervous system. However, in the case of Xenical™, side effects such as fat stool, abdominal pain, vomiting, itching, and liver damage have been reported. In the case of Reductil™, it is believed to cause serious cardiovascular side effects as well as side effects such as headache, loss of appetite, insomnia, and constipation. Have been reported.

Diabetes mellitus is a disease caused by insufficient secretion of insulin or not performing a normal function, and is characterized by hyperglycemia in which the concentration of glucose in the blood increases and glucose is excreted into the urine. Diabetes treatments currently used include PPAR-γ activators, GLP-1 derivatives, and DPP-IV inhibitors, but these conventional drugs are reported to have side effects showing toxicity to weight gain and liver, kidney, muscle, and heart. have.

Hyperlipidemia is a disease that causes inflammation by accumulating on the walls of blood vessels while more fatty substances are present in the blood than necessary, and as a result, it is known as a disease that causes cardiovascular diseases such as myocardial infarction, stroke or cerebral infarction. Currently used drugs for hyperlipidemia include'statin'-based drugs that have HMG-CoA reductase inhibitory activity, but when used for a long time, they are reported to have side effects showing toxicity to the liver or muscles.

Dyslipidemia refers to a condition in which total cholesterol, LDL cholesterol, or triglyceride in the blood is increased, or a condition in which HDL cholesterol is decreased, and is known to increase the risk of cardiovascular diseases such as heart attack and stroke. Currently, drugs that can be used as treatments for dyslipidemia include Bayer's BAY13-9952 (implitapide), a drug that inhibits the activity of MTP (microsomal triglyceride transfer protein), but these drugs have specific mechanisms of action in cells. There is a problem that it may cause side effects because it is not identified as.

Non-alcoholic fatty liver refers to fatty liver that occurs due to causes other than alcohol among fatty liver, and refers to a case in which fatty acids are accumulated in the parenchymal cells of the liver in the form of triglycerides by more than 5%. Pathologically, it is classified into simple steatosis and steatohepatitis with inflammation. It is known that long-term neglect can lead to serious liver diseases such as hepatitis, liver fibrosis, and cirrhosis. Non-alcoholic fatty liver has difficulty in developing a treatment because the cause of the onset of non-alcoholic fatty liver has not yet been clearly identified. The development of effective drugs is also difficult.

Currently, the development of excellent therapeutic agents for overall obesity or metabolic diseases is inadequate, and various side effects such as the above are also reported for treatments for individual specific diseases.Therefore, the treatment efficacy for obesity or metabolic diseases is excellent, but safe without side effects. There is an urgent need for the development of therapeutic agents.

Journal of Life Science 2006, Vol. 16, No. 7, pp. 1071-1079 J. Korean Soc. Food Sci. Nutr. 2011, Vol. 40, No. 11, pp. 1544-1547

The main object of the present invention is to provide a composition for the prevention, improvement or treatment of obesity or metabolic diseases, comprising a complex extract of dohwa and lower leaves as an active ingredient.

Specifically, an object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity or metabolic diseases, including the dohwa and lower leaf complex extract or a fraction thereof as an active ingredient.

Another object of the present invention is to provide a food composition for the prevention or improvement of obesity or metabolic diseases, including the dohwa and lower leaf complex extract or a fraction thereof as an active ingredient.

In order to achieve the object of the present invention, the present invention provides a pharmaceutical composition or a food composition containing a complex extract or a fraction thereof as an active ingredient. In the following, each will be examined in detail.

Pharmaceutical composition for preventing or treating obesity or metabolic disease

As an aspect for achieving the object of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of obesity or metabolic disease, comprising the dohwa and lower leaf complex extract or a fraction thereof as an active ingredient.

As used herein, the term "Peach Blossom" refers to a flower of a peach tree, a radiating tree, or a mountain radish tree belonging to the Rosaceae family. Dohwa is a bisexual flower with a diameter of about 2.5 to 3.5 cm. Usually, there are varieties such as pink, white, and deep red. Dohwa is collected during the flowering period in mid-April or early May, dried in the shade, and used as herbal medicine. In the present invention, the drawing may be a flower of a plant having a scientific name of Prunus persica or Prunus davidiana , but is not limited thereto.

The term "dohwa extract" used in the present invention means an extract obtained by extracting peach blossoms or buds with water or an organic solvent.

The term "lower leaf" used in the present invention means a leaf of a lotus flower belonging to the lotus family (Nelumbonaceae). The lower leaf is semicircular or row fan-shaped, but when opened, it is circular, 20 to 50 cm in diameter, and the edge of the leaf is flat or wavy. The upper surface of the leaf is dark green or yellow-green, and the lower surface is slightly glossy, and 21 to 22 lines of protruding veins extend in all directions from the center of the petiole. In the present invention, the lower leaf may be a leaf of a plant having a scientific name of Nelumbo nucifera , but is not limited thereto.

The term "lower leaf extract" as used in the present invention means an extract obtained by extracting lotus leaves with water or an organic solvent.

In the present invention, the "dohwa and lower leaf complex extract" is a mixture of the dohwa extract and the lower leaf extract, or includes both extracts of the dohwa and lower leaf mixture.

In the present invention, the dohwa extract and the lower leaf extract may be mixed in a weight ratio of 10:1 to 1:10, and preferably 5:1 to 1:5, more preferably 3 It can be mixed from :1 to 1:3.

In addition, in the present invention, the mixture of the drawing and the lower leaf may also be mixed in a weight ratio of 10:1 to 1:10, preferably 5:1 to 1:5, more preferably 3:1 to 1:3 Can be mixed into.

The term "extract" as used in the present invention refers to an extract obtained by extracting natural substances, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a prepared product or purified product of the extract, or a mixture thereof. , The extract itself and all formulations that can be formed using the extract are included.

The method of preparing the extract is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method, immersion extraction method, high temperature and high pressure steam extraction method, etc., which may be performed alone or in combination of two or more methods. have.

In the present invention, the kind of the extraction solvent used to extract natural substances is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent may include water, alcohol, or a mixed solvent thereof, and when alcohol is used as a solvent, it is preferably extracted with C ₁ -C ₄ alcohol, more preferably methanol or ethanol. And most preferably water, 30% to 80% methanol (v/v), 30% to 80% ethanol (v/v) extract. The extraction solvent is preferably 2 to 20 times the dry weight of the drawing or lower leaf.

According to an embodiment of the present invention, the dohwa and the lower leaf complex extract are respectively shredded and then separately put in an extraction container with water or C ₁ or C ₂ lower alcohol or a mixed solvent thereof, preferably water, 50% methanol (v/v), 30% ethanol (v/v), or 70% ethanol (v/v) was added and extraction was performed at a constant temperature to prepare a single extract, followed by mixing in an appropriate ratio.

However, the method is not limited to the method of preparing the drawing and lower leaf complex extract as an example, and the drawing and lower leaf complex extract of the present invention is all the drawing prepared according to a method known in the art or similar technical field. And a lower leaf complex extract. In the production method according to the present invention, when the extraction solvent is water, 100°C, 50% methanol (v/v), 80°C, 30% ethanol (v/v), 85°C, 70% ethanol ( In the case of v/v), it is preferable to perform extraction at 80°C. Thereafter, the extract may be additionally subjected to a process of filtration, concentration under reduced pressure, and dry powder.

In the present invention, the 50% methanol extract of the drawing and the lower leaf refers to a methanol extract of about 50%, and may include 45% to 55% methanol extract. The 30% ethanol extract of the drawing and the lower leaf means an ethanol extract of about 30%, and may include 25% to 35% ethanol extract. The 70% ethanol extract of the drawing and the lower leaf means an ethanol extract of about 70%, and may include an ethanol extract of 65% to 75%.

As used herein, the term "fraction" means a result obtained by performing fractionation in order to separate a specific component or a specific component group from a mixture containing several different constituents.

The fractionation method for obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art. Non-limiting examples of the fractionation method include a method of obtaining a fraction from the extract by treating an extract obtained by extracting a natural substance with a predetermined solvent.

In the present invention, the kind of the fractionation solvent used to obtain the fraction is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the fractionation solvent include polar solvents such as water and alcohol; Non-polar solvents, such as hexane, ethyl acetate, chloroform, and dichloromethane, etc. are mentioned. These may be used alone or in combination of two or more. In the case of using alcohol in the fractionation solvent, C ₁ -C ₄ alcohol may be preferably used.

The present inventors were the first to find out that the complex extract of Dohwa and lower lobe has a remarkable therapeutic effect on metabolic diseases including obesity, diabetes, hyperlipidemia, dyslipidemia and non-alcoholic fatty liver. In particular, according to the embodiment of the present invention, it was confirmed that the composite extract of Dowha and lower lobe has superior weight loss effect and fat suppression effect of high-fat diet mice compared to each of Dowha or lower lobe single extract (Figs. 1 and 2), obesity, It was confirmed that the effect of inhibiting blood factors in metabolic diseases such as diabetes, hyperlipidemia, non-alcoholic fatty liver and dyslipidemia was excellent (FIG. 3).

As used herein, the term "metabolic disease" refers to diseases caused by metabolic abnormalities such as sugars, lipids, proteins, vitamins and minerals, and specific examples are obesity due to abnormal blood sugar metabolism, diabetes, hyperlipidemia due to abnormal lipid metabolism, Dyslipidemia, non-alcoholic fatty liver, and the like.

Diseases to be prevented or treated using the present invention include all obesity or metabolic diseases, more preferably selected from the group consisting of obesity, diabetes, hyperlipidemia, dyslipidemia, and nonalcoholic fatty liver due to abnormal blood sugar metabolism. I can.

The term "obesity" used in the present invention generally refers to a state of fattening, that is, an excessive accumulation of fat in the body, and pathologically, the body obesity index (Body mass index: body weight (kg)) It means that the value divided by the square of the height (m)) is 25 or more in Korea and 30 or more according to the World Health Organization (WHO). In most cases, it means that the weight is more than normal, but even if you are not overweight, if the proportion of fat among the components of the body is high, it is diagnosed as obesity. Obesity is a disease that affects both adults and children, and it is known that fatty acids and glucose, which are introduced into fat cells from plasma, are esterified and accumulated mainly in the form of triglycerides in individuals with obesity symptoms.

The term "diabetes" as used in the present invention is a disease caused by insufficient secretion of insulin or not performing a normal function, characterized by hyperglycemia in which the concentration of glucose in the blood is high and glucose is excreted into the urine. It is known that retinopathy, renal dysfunction, neuropathy, and cardiovascular abnormalities may occur.

The term "hyperlipidemia" as used in the present invention refers to a disease that causes inflammation by accumulating on the walls of blood vessels while more fatty substances are present in the blood than necessary, and as a result, a disease that causes cardiovascular disease. Does not appear, but it is known that symptoms may occur due to complications. For example, it is known that pancreatitis may occur due to an increase in triglycerides in the blood, xanthoma may occur in the Achilles tendon, or xanthelasma may occur in the eyelid.

As used herein, the term "dyslipidemia" refers to a condition in which total cholesterol, LDL cholesterol, or triglycerides in blood is increased, or a condition in which HDL cholesterol is reduced, and refers to the risk of cardiovascular diseases such as heart attack and stroke. It is known to increase. Dyslipidemia can be caused by smoking, drinking, etc., and it can also be caused by genetic factors. It is known that the risk of dyslipidemia increases when there are diseases such as obesity, diabetes, and high blood pressure.

The term "non-alcoholic fatty liver" as used in the present invention refers to fatty liver that occurs due to causes other than alcohol among fatty liver, and refers to a case in which fatty acids are accumulated in the parenchymal cells of the liver in the form of triglycerides by 5% or more. Pathologically, it is classified into simple steatosis and steatohepatitis with inflammation. It is known that long-term neglect can lead to serious liver diseases such as hepatitis, liver fibrosis, and cirrhosis.

The complex extract of the present invention not only has a significantly superior fat suppression effect compared to each of the dohwa or lower lobe single extracts (Figs. 1 and 2), but also of blood factors representing metabolic diseases such as obesity, diabetes, hyperlipidemia, non-alcoholic fatty liver and dyslipidemia. It shows an excellent effect on inhibition (Fig. 3). Therefore, the dohwa and lower lobe complex extract of the present invention can be usefully used in the prevention or treatment of obesity or metabolic diseases.

The pharmaceutical composition comprising the complex extract of the present invention or a fraction thereof may further include a suitable carrier, excipient, or diluent commonly used in the preparation of pharmaceutical compositions. In this case, the content of the complex extract or fraction contained in the composition is not particularly limited, but is preferably included in an amount of 10 to 70% by weight based on the total weight of the composition, but is not limited thereto.

The composition comprising the complex extract of the present invention or a fraction thereof, according to a conventional method, respectively, of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions. It can be formulated and used in a form. Carriers, excipients and diluents that can be included in the composition in the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oils. In the case of formulation, it is prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants that are usually used. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient, such as starch, calcium carbonate, sucrose or lactose, in the complex extract and its fractions, It is prepared by mixing gelatin or the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, liquid solutions, emulsions, syrups, etc., and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to water and liquid paraffin, which are commonly used simple diluents. have. Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like can be used.

A preferred dosage of the complex extract of the present invention may vary depending on the condition and weight of the patient, the degree of disease, the drug form, the route and duration of administration, and may be appropriately selected by those skilled in the art. Administration may be administered once a day, or may be divided several times.

The pharmaceutical composition of the present invention can be administered to mammals such as mice, mice, livestock, and humans by various routes. All modes of administration can be expected, for example, oral, rectal or intravenous, intramuscular, subcutaneous injection and the like.

Food composition for preventing or improving obesity or metabolic disease

As another aspect for achieving the object of the present invention, the present invention provides a food composition for preventing or improving obesity or metabolic disease, comprising a dohwa and lower leaf complex extract or a fraction thereof as an active ingredient.

The Dohwa and lower leaf complex extract of the present invention or a fraction thereof is derived from a natural product, and its safety has been proven, so it can be used as a food composition.

The food composition comprising the dohwa and lower leaf complex extract of the present invention or a fraction thereof as an active ingredient exhibits excellent weight loss efficacy and excellent obesity or metabolic disease improvement effect.

The dohwa and lower leaf complex extract of the present invention or a fraction thereof is preferably included in an amount of 10% to 70% by weight based on the total weight of the composition, but is not limited thereto.

The food composition of the present invention may contain additional ingredients that are commonly used in food compositions to improve odor, taste, vision, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), and copper (Cu) may be included. In addition, amino acids such as lysine, tryptophan, cysteine, and valine may be included. In addition, preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dihydroacetate, etc.), disinfectants (bleaching and highly bleaching, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene (BHT) ), colorants (tar color, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (MSG sodium glutamate, etc.), sweeteners (dulsin, cyclamate, saccharin, sodium, etc.), Food additives such as flavorings (vanillin, lactones, etc.), expanding agents (alum, D-potassium hydrogen stannate, etc.), reinforcing agents, emulsifiers, thickeners (thickening agents), coating agents, gum base agents, foam inhibitors, solvents, improvers, etc. Can be added. The additive is selected according to the type of food and used in an appropriate amount.

In one embodiment of the present invention, the food composition may be a health functional food or a health supplement.

The term "health food" used in the present invention refers to a food having an active health maintenance or promotion effect compared to general food, and "health supplement food" refers to a food for health supplement purposes. do. In some cases, the terms functional food, health food, and health supplement are used interchangeably. The food can be prepared in various forms such as tablets, capsules, powders, granules, liquids, and pills to obtain useful effects.

The term "functional food" used in the present invention is the same term as food for special health use (FoSHU), and is processed to effectively display bioregulatory functions in addition to nutrition supply. It means food with high effect.

As a specific example of the health functional food of the present invention, it is possible to manufacture a processed food with good storage properties while making use of the characteristics of agricultural products, livestock products, or aquatic products by using the dohwa and lower leaf complex extracts or fractions thereof. The health functional food comprising the extract or fractions thereof of the present invention is not particularly limited, but preferably margarine, fat continuous or water continuous or bicontinuous spread, Reduced fat spreads, chocolate, or confectionery such as chocolate coatings or chocolate fillings or bakery fillings, ice cream, ice cream coatings, ice cream inclusions, dressings, mayonnaise, cheese, cream substitutes, dry soups, drinks, cereal bars, sauces , Snack bars, dairy products, clinical nutritional foods, children's foods, etc. can be used.

The dohwa and lower lobe complex extract of the present invention or its fractions are excellent in efficacy against obesity or metabolic diseases, are derived from natural products and have no side effects, so they can be variously used for prevention, improvement or treatment of obesity or metabolic diseases.

1 is a graph comparing the total body weight and weight gain of a single extract (shown as a figure), a single extract (shown as a lower lobe), and a composite extract of the present invention (shown as composite 1 or composite 2) in a high-fat mouse model. .
Figure 2 shows the abdominal fat weight (abnominal fat weight), around the kidneys of a single extract (shown as a figure), a single extract (shown as a lower lobe), and a composite extract of the present invention (shown as a composite 1 or 2) in a high-fat mouse model This is a graph comparing perirenal fat weight, mesenteric fat weight, and total fat weight.
Figure 3 shows the liver values (ALT and AST), blood sugar (glucose) of a single extract (shown as a figure), a single extract (shown as a lower lobe) and a composite extract of the present invention (shown as a composite 1 or 2) in a high-fat mouse model. ) And triglycerides (TG).

Hereinafter, the present invention will be described in more detail through manufacturing examples and examples. However, these Preparation Examples and Examples are for illustrative purposes only, and the scope of the present invention is not limited to these Preparation Examples and Examples.

<Preparation Example> Preparation of single extract or complex extract

Preparation Example 1: Preparation of Dohwa single extract

After cutting the dried product, it was placed in an extraction container, and water was added thereto, followed by repeating twice for 3 hours at 100° C. for reflux extraction. The extract was filtered through a filter paper, concentrated under reduced pressure with a rotary vacuum evaporator (EYELA, japan), and then freeze-dried with a freeze dryer (OPR-FDY-8612, OPERON, KOREA) to prepare a single extract of Dohwa. .

Preparation Example 2: Preparation of single lower leaf extract

The dried lower leaf was minced, extracted and freeze-dried in the same manner as in Preparation Example 1 to prepare a lower leaf single extract.

Preparation Example 3: Preparation of the composite extract of the drawing and lower leaves of the present invention

The composite extract of the present invention was prepared by the weight ratio of the dohwa single extract prepared in Preparation Example 1 and the lower leaf single extract prepared in Preparation Example 2 below.

Manufacturing example Drawing Lower leaves 3-1 One One 3-2 2 One

Preparation Example 4: Preparation of the composite extract of the drawing and lower leaves of the present invention

The dried material of the drawing and the lower leaf was minced and mixed at the weight ratio shown in Table 2 below, and extracted and freeze-dried in the same manner as in Preparation Example 1 to prepare a composite extract of the present invention.

Manufacturing example Drawing Lower leaves 4-1 One 1.35 4-2 One 0.65

Example 1: Checking the effect of reducing body fat percentage in a high fat diet mouse model

In order to examine the weight loss effect of the dohwa and lower lobe complex extract of the present invention, a 21-day-old (3-week-old) male mouse C57BL/6 was purchased and adapted while freely feeding water and feed (chow diet) for 1 week. When the experimental animals are 4 weeks old, the weight of the experimental animals is measured and placed so that the average weight deviation per cage is less than 0.1 g, and then a total of 6 groups by different dietary conditions as shown in Table 3 below (each n = Divided into 8). Then, for a total of 8 weeks, a high-fat feed (60% kcal fat) mixed with extracts corresponding to each group in Table 3 was supplied once every 3 to 4 days.

feed Supply of extract Supply method Number of animals (n) General Standard feed - Free meal 8 horses Control (water) 60% fat content - Free meal 8 horses Preparation Example 1 (drawing) 60% fat content 2 g/kg diet Free meal 8 horses Preparation Example 2 (lower leaf) 60% fat content 2 g/kg diet Free meal 8 horses Preparation Example 3-1 (Composite 1) 60% fat content 2 g/kg diet Free meal 8 horses Preparation Example 3-2 (Composite 2) 60% fat content 2 g/kg diet Free meal 8 horses

As a result, the mouse model fed the dohwa and lower lobe complex extract of the present invention showed superior weight loss effect than the mouse model fed the dohwa single extract. In particular, although the single lower leaf extract itself did not show any weight loss effect, in the case of the dohwa and lower leaf complex extract, the weight loss effect was reduced by half compared to the dohwa single extract. It was confirmed that it was superior to a single extract (FIG. 1). Meanwhile, in order to confirm that the weight loss effect was a fat suppression effect, the amount of fat for each part of the experimental animal was measured and recorded. Specifically, the adipose tissue of the experimental animal was divided into abdominal fat, perirenal fat, and mesentric fat after the experiment was completed, and the weight was measured.

As a result, it was confirmed that the mouse model fed the dohwa and the lower lobe complex extract of the present invention has superior inhibitory effect on the amount of fat in all regions than the mouse model fed with the dohwa single extract or the lower lobe single extract (Fig. 2).

Through the above results, it was found that the dohwa and lower lobe complex extract of the present invention exhibits significantly better fat suppression effect than that of the dohwa single extract or lower lobe single extract, and can be usefully used in the prevention or treatment of metabolic diseases such as obesity I can.

Example 2: Checking the effect of reducing blood obesity or metabolic disease indicators in a high fat diet mouse model

In order to further confirm that the composite extract of Fig. and lower lobe of the present invention is effective in preventing or treating metabolic diseases, liver level ALT in plasma isolated from the blood collected before the adipose tissue of the mouse used in Example 1 was removed ( Alanine aminotransferase, alanine aminotransferase) and AST (aspartate aminotransferase), blood glucose level, and triglyceride (TG) levels were measured.

As a result, when the dohwa and lower lobe complex extract of the present invention is fed into a mouse model ingesting a high fat diet, chronically elevated blood ALT, AST, blood sugar and triglycerides in metabolic diseases such as obesity, diabetes, hyperlipidemia, dyslipidemia, and non-alcoholic fatty liver. It was confirmed that both (TG) values showed a remarkably superior synergistic effect than the inhibitory effect exhibited by a mouse model fed with a single extract of dowha or a single extract of lower leaves (FIG. 3).

Through the above results, the dohwa and lower lobe complex extract of the present invention exhibits a remarkably superior synergistic effect than the metabolic disease treatment effect of the dowha single extract or the lower lobe single extract. It can be seen that it can be usefully used in the prevention or treatment of diseases.

In the present specification, details that can be sufficiently recognized and inferred by those of ordinary skill in the technical field of the present invention have been omitted, and the technical spirit or essential configuration of the present invention other than the specific examples described in the present specification is changed. More various modifications are possible within the range that does not. Accordingly, the present invention may be implemented in a manner different from that specifically described and illustrated in the present specification, which is a matter that can be understood by those of ordinary skill in the technical field of the present invention.

Claims (5)

As a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver comprising a dohwa and lower leaf complex extract or a fraction thereof as an active ingredient,
The composite extract is a mixture containing a weight ratio of 1:1 to 2:1 of the dohwa extract and the lower leaf extract, or an extract of a mixture comprising the dohwa and lower leaves in a weight ratio of 1:1 to 2:1 as,
The composite extract or a fraction thereof is a pharmaceutical composition having a weight loss effect.
The pharmaceutical composition of claim 1, wherein the complex extract is extracted with water, C ₁ -C ₄ alcohol or a mixture thereof.
delete As a food composition for the prevention or improvement of non-alcoholic fatty liver comprising a dohwa and lower leaf complex extract or a fraction thereof as an active ingredient,
The complex extract as a food composition that is a mixture containing the dohwa extract and the lower leaf extract in a weight ratio of 1:1 to 2:1, or the extract of a mixture comprising the dohwa and lower leaves in a weight ratio of 1:1 to 2:1 ,
The complex extract or a fraction thereof is a food composition having a weight loss effect.
The food composition according to claim 4, wherein the composition is a health functional food or a health supplement.

Images